Research & Literature

Clinical characteristics of idiopathic pulmonary fibrosis patients with gender, age, and physiology staging at Okinawa Chubu Hospital.

Kishaba T, Shimaoka Y, Fukuyama H, et al.

Journal of thoracic disease 2015; (7(5)):843-9 doi:10.3978/j.issn.2072-1439.2015.04.54.

In-Hospital Mortality after Surgical Lung Biopsy for Interstitial Lung Disease in the United States. 2000 to 2011.

Hutchinson JP, Fogarty AW, McKeever TM, Hubbard RB

American journal of respiratory and critical care medicine 2016; (193(10)):1161-7 doi:10.1164/rccm.201508-1632OC.

Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.

Reichmann WM, Yu YF, Macaulay D, et al.

BMC pulmonary medicine 2015; (15()):167 doi:10.1186/s12890-015-0161-5.

Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives.

Kreuter M, Bonella F, Wijsenbeek M, et al.

BioMed research international 2015; (2015()):329481 doi:10.1155/2015/329481.

Epidemiology of Idiopathic Pulmonary Fibrosis in Northern Italy.

Harari S, Madotto F, Caminati A, et al.

PloS one 2016; (11(2)):e0147072 doi:10.1371/journal.pone.0147072.

Consensus document for the diagnosis and treatment of idiopathic pulmonary fibrosis: Joint Consensus of Sociedade Portuguesa de Pneumologia, Sociedade Portuguesa de Radiologia e Medicina Nuclear e Sociedade Portuguesa de Anatomia Patológica.

Robalo Cordeiro C, Campos P, Carvalho L, et al.

Revista portuguesa de pneumologia 2016; (22(2)):112-22.

Management of interstitial lung disease associated with connective tissue disease.

Mathai SC, Danoff SK

BMJ (Clinical research ed.) 2016; (352()):h6819 doi:10.1136/bmj.h6819.

Pharmacological management of IPF.

Borie R, Justet A, Beltramo G, et al.

Respirology (Carlton, Vic.) 2016; (21(4)):615-25 doi:10.1111/resp.12778.

Targeted treatment of idiopathic pulmonary fibrosis: one step at a time.

Richeldi L

The European respiratory journal 2016; (47(5)):1321-3 doi:10.1183/13993003.00389-2016.

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.

Collard HR, Ryerson CJ, Corte TJ, et al.

American journal of respiratory and critical care medicine 2016; (194(3)):265-75 doi:10.1164/rccm.201604-0801CI.

Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria.

Raghu G, Wells AU, Nicholson AG, et al.

American journal of respiratory and critical care medicine 2017; (195(1)):78-85 doi:10.1164/rccm.201602-0402OC.

Idiopathic pulmonary fibrosis: another step in understanding the burden of this disease.

Hutchinson J

The European respiratory journal 2016; (48(1)):26-8 doi:10.1183/13993003.00907-2016.

Risk factors for an acute exacerbation of idiopathic pulmonary fibrosis.

Kakugawa T, Sakamoto N, Sato S, et al.

Respiratory research 2016; (17(1)):79 doi:10.1186/s12931-016-0400-1.

Idiopathic Pulmonary Fibrosis: Treatment and Prognosis.

Fujimoto H, Kobayashi T, Azuma A

Clinical medicine insights. Circulatory, respiratory and pulmonary medicine 2015; (9(Suppl 1)):179-185 doi:10.4137/CCRPM.S23321.

Optimizing quality of life in patients with idiopathic pulmonary fibrosis.

van Manen MJ, Geelhoed JJ, Tak NC, Wijsenbeek MS

Therapeutic advances in respiratory disease 2017; (11(3)):157-169 doi:10.1177/1753465816686743.

CT Findings, Radiologic-Pathologic Correlation, and Imaging Predictors of Survival for Patients With Interstitial Pneumonia With Autoimmune Features.

Chung JH, Montner SM, Adegunsoye A, et al.

AJR. American journal of roentgenology 2017; (208(6)):1229-1236 doi:10.2214/AJR.16.17121.

Current approaches to the management of idiopathic pulmonary fibrosis.

Raghu G, Richeldi L

Respiratory medicine 2017; (129()):24-30 doi:10.1016/j.rmed.2017.05.017.

Utility of Flexible Bronchoscopic Cryobiopsy for Diagnosis of Diffuse Parenchymal Lung Diseases.

Lentz RJ, Taylor TM, Kropski JA, et al.

Journal of bronchology & interventional pulmonology 2018; (25(2)):88-96 doi:10.1097/LBR.0000000000000401.

Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.

Jo HE, Troy LK, Keir G, et al.

Respirology (Carlton, Vic.) 2017; (22(7)):1436-1458 doi:10.1111/resp.13146.

Fatal diffuse alveolar haemorrhage mimicking acute exacerbation in idiopathic pulmonary fibrosis treated with nintedanib.

Sugino K, Nakamura Y, Sekiya M, et al.

Respirology case reports 2017; (5(6)):e00258 doi:10.1002/rcr2.258.

Factors affecting dyspnea after the 6-minute walk test in idiopathic pulmonary fibrosis patients presenting with exercise-induced hypoxemia.

Morino A, Takahashi H, Chiba H, Ishiai S

Journal of physical therapy science 2017; (29(8)):1458-1462 doi:10.1589/jpts.29.1458.

Clinical impact of depression and anxiety in patients with idiopathic pulmonary fibrosis.

Lee YJ, Choi SM, Lee YJ, et al.

PloS one 2017; (12(9)):e0184300 doi:10.1371/journal.pone.0184300.

A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.

Birring SS, Wijsenbeek MS, Agrawal S, et al.

The Lancet. Respiratory medicine 2017; (5(10)):806-815 doi:10.1016/S2213-2600(17)30310-7.

Diagnostic utility of surgical lung biopsies in elderly patients with indeterminate interstitial lung disease.

Vaszar LT, Larsen BT, Swanson KL, et al.

Respirology (Carlton, Vic.) 2018; (23(5)):507-511 doi:10.1111/resp.13223.

Smoking-related lung abnormalities on computed tomography images: comparison with pathological findings.

Iwasawa T, Takemura T, Ogura T

Japanese journal of radiology 2018; (36(3)):165-180 doi:10.1007/s11604-017-0713-0.

IPF and CPFE - the two different entities or two different presentations of the same disease?

Kwiatkowska S

Advances in respiratory medicine 2018; (86(1)):23-26 doi:10.5603/ARM.a2017.0049.

Impact of Pulmonary Rehabilitation on Exercise Tolerance and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A SYSTEMATIC REVIEW AND META-ANALYSIS.

Gomes-Neto M, Silva CM, Ezequiel D, et al.

Journal of cardiopulmonary rehabilitation and prevention 2018; (38(5)):273-278 doi:10.1097/HCR.0000000000000273.

Diagnostic Ability of a Dynamic Multidisciplinary Discussion in Interstitial Lung Diseases: A Retrospective Observational Study of 938 Cases.

De Sadeleer LJ, Meert C, Yserbyt J, et al.

Chest 2018; (153(6)):1416-1423 doi:10.1016/j.chest.2018.03.026.

Idiopathic Pulmonary Fibrosis.

Lederer DJ, Martinez FJ

The New England journal of medicine 2018; (378(19)):1811-1823 doi:10.1056/NEJMra1705751.

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Raghu G, Remy-Jardin M, Myers JL, et al.

American journal of respiratory and critical care medicine 2018; (198(5)):e44-e68 doi:10.1164/rccm.201807-1255ST.

Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives.

Graney BA, Lee JS

Patient related outcome measures 2018; (9()):321-328 doi:10.2147/PROM.S144425.

Implications of the diagnostic criteria of idiopathic pulmonary fibrosis in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.

Jo HE, Glaspole I, Goh N, et al.

Respirology (Carlton, Vic.) 2019; (24(4)):361-368 doi:10.1111/resp.13427.

Six-minute walk distance and survival time in patients with idiopathic pulmonary fibrosis in Brazil.

Mancuzo EV, Soares MR, Pereira CAC

Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia 2018; (44(4)):267-272 doi:10.1590/S1806-37562018000000049.

Diagnosis of Idiopathic Pulmonary Fibrosis in a Possible Usual Interstitial Pneumonia Pattern: a meta-analysis.

Kim H, Yoon SH, Hong H, et al.

Scientific reports 2018; (8(1)):15886 doi:10.1038/s41598-018-34230-z.

IL-17A contributes to HSV1 infection-induced acute lung injury in a mouse model of pulmonary fibrosis.

Chen T, Qiu H, Zhao MM, et al.

Journal of cellular and molecular medicine 2019; (23(2)):908-919 doi:10.1111/jcmm.13992.

The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone.

Harari S, Caminati A, Confalonieri M, et al.

The clinical respiratory journal 2019; (13(3)):166-173 doi:10.1111/crj.12999.

Progress in Understanding and Treating Idiopathic Pulmonary Fibrosis.

Kropski JA, Blackwell TS

Annual review of medicine 2019; (70()):211-224 doi:10.1146/annurev-med-041317-102715.

Imaging in idiopathic pulmonary fibrosis: diagnosis and mimics.

Hochhegger B, Marchiori E, Zanon M, et al.

Clinics (Sao Paulo, Brazil) 2019; (74()):e225 doi:10.6061/clinics/2019/e225.

Tissue Continues to Be the Issue: Role of Histopathology in the Context of Recent Updates in the Radiologic Classification of Interstitial Lung Diseases.

Raparia K, Raj R

Archives of pathology & laboratory medicine 2019; (143(1)):30-33 doi:10.5858/arpa.2018-0134-RA.

Quantitative CT analysis of honeycombing area predicts mortality in idiopathic pulmonary fibrosis with definite usual interstitial pneumonia pattern: A retrospective cohort study.

Nakagawa H, Ogawa E, Fukunaga K, et al.

PloS one 2019; (14(3)):e0214278 doi:10.1371/journal.pone.0214278.

[Selection of lung transplant candidates in France in 2019].

Falque L, Gheerbrant H, Saint-Raymond C, et al.

Revue des maladies respiratoires 2019; (36(4)):508-518 doi:10.1016/j.rmr.2018.03.009.

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

Distler O, Highland KB, Gahlemann M, et al.

The New England journal of medicine 2019; (380(26)):2518-2528 doi:10.1056/NEJMoa1903076.

Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis.

Dempsey TM, Sangaralingham LR, Yao X, et al.

American journal of respiratory and critical care medicine 2019; (200(2)):168-174 doi:10.1164/rccm.201902-0456OC.

Highlights of high-resolution computed tomography imaging in evaluation of complications and co-morbidities in idiopathic pulmonary fibrosis.

Ricci F, Pugliese L, Cavallo AU, et al.

Acta radiologica (Stockholm, Sweden : 1987) 2020; (61(2)):204-218 doi:10.1177/0284185119857435.

Interstitial Lung Disease: Update on the Role of Computed Tomography in the Diagnosis of Idiopathic Pulmonary Fibrosis.

Chen L, Halai V, Leandru A, Wallis A

Journal of computer assisted tomography 2019; (43(6)):898-905 doi:10.1097/RCT.0000000000000915.

Idiopathic Pulmonary Fibrosis and Lung Transplantation: When it is Feasible.

Balestro E, Cocconcelli E, Tinè M, et al.

Medicina (Kaunas, Lithuania) 2019; (55(10)) doi:10.3390/medicina55100702.

Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease.

Hoffmann-Vold AM, Weigt SS, Saggar R, et al.

EBioMedicine 2019; (50()):379-386 doi:10.1016/j.ebiom.2019.10.050.

Guidelines of the Polish Respiratory Society for diagnosis and treatment of idiopathic pulmonary fibrosis.

Piotrowski WJ, Bestry I, Białas AJ, et al.

Advances in respiratory medicine 2020; (88(1)):41-93 doi:10.5603/ARM.2020.0081.

Exercise and Chronic Obstructive Pulmonary Disease (COPD).

Fiorentino G, Esquinas AM, Annunziata A

Advances in experimental medicine and biology 2020; (1228()):355-368 doi:10.1007/978-981-15-1792-1_24.

Smoking-associated interstitial lung disease: update and review.

Dawod YT, Cook NE, Graham WB, et al.

Expert review of respiratory medicine 2020; (14(8)):825-834 doi:10.1080/17476348.2020.1766971.

Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry.

Behr J, Prasse A, Wirtz H, et al.

The European respiratory journal 2020; (56(2)) doi:10.1183/13993003.02279-2019.

Current therapies for patients with acute exacerbation of idiopathic pulmonary fibrosis.

Zhu LL, Dai HP, Wang C

Chinese medical journal 2020; (133(12)):1470-1472 doi:10.1097/CM9.0000000000000864.

Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis.

Adams TS, Schupp JC, Poli S, et al.

Science advances 2020; (6(28)):eaba1983 doi:10.1126/sciadv.aba1983.

Changes in management of idiopathic pulmonary fibrosis: impact on disease severity and mortality.

Hyldgaard C, Møller J, Bendstrup E

European clinical respiratory journal 2020; (7(1)):1807682 doi:10.1080/20018525.2020.1807682.

Managing Dyspnea in Individuals With Idiopathic Pulmonary Fibrosis.

Fenwick KE, Swan BA

Journal of hospice and palliative nursing : JHPN : the official journal of the Hospice and Palliative Nurses Association 2020; (22(6)):447-455 doi:10.1097/NJH.0000000000000687.

Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study.

Veit T, Barnikel M, Crispin A, et al.

Respiratory research 2020; (21(1)):270 doi:10.1186/s12931-020-01524-8.

Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis.

Miyashita K, Kono M, Saito G, et al.

The clinical respiratory journal 2021; (15(3)):336-344 doi:10.1111/crj.13304.

Clinical diagnosis of patients subjected to surgical lung biopsy with a probable usual interstitial pneumonia pattern on high-resolution computed tomography.

Tibana RCC, Soares MR, Storrer KM, et al.

BMC pulmonary medicine 2020; (20(1)):299 doi:10.1186/s12890-020-01339-9.

Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg).

Krauss E, Tello S, Wilhelm J, et al.

Journal of clinical medicine 2020; (9(11)) doi:10.3390/jcm9113763.

Histologic features suggesting connective tissue disease in idiopathic pulmonary fibrosis.

Kim HC, Song JS, Park S, et al.

Scientific reports 2020; (10(1)):21137 doi:10.1038/s41598-020-78140-5.

Twenty-four-hour ambulatory oximetry monitoring in a patient with idiopathic pulmonary fibrosis for assisting in the discharge instruction on activities of daily living: a case report.

Sekikawa K, Aizawa F, Sekikawa N, et al.

Journal of physical therapy science 2020; (32(11)):768-771 doi:10.1589/jpts.32.768.

Idiopathic pulmonary fibrosis: What nurses need to know.

Pruitt B

Nursing 2021; (51(1)):22-29 doi:10.1097/01.NURSE.0000724352.48335.1b.

Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review.

Hoffmann-Vold AM, Maher TM, Philpot EE, et al.

ERJ open research 2021; (7(1)) doi:10.1183/23120541.00235-2020.

Evaluation of Correlations between Genetic Variants and High-Resolution Computed Tomography Patterns in Idiopathic Pulmonary Fibrosis.

Baratella E, Ruaro B, Giudici F, et al.

Diagnostics (Basel, Switzerland) 2021; (11(5)) doi:10.3390/diagnostics11050762.

The challenge of diagnosing interstitial lung disease by HRCT: state of the art and future perspectives.

Rea G, Bocchino M

Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia 2021; (47(3)):e20210199 doi:10.36416/1806-3756/e20210199.

Global incidence and prevalence of idiopathic pulmonary fibrosis.

Maher TM, Bendstrup E, Dron L, et al.

Respiratory research 2021; (22(1)):197 doi:10.1186/s12931-021-01791-z.

Sex Differences in the Incidence and Outcomes of Patients Hospitalized by Idiopathic Pulmonary Fibrosis (IPF) in Spain from 2016 to 2019.

López-Muñiz Ballesteros B, López-Herranz M, Lopez-de-Andrés A, et al.

Journal of clinical medicine 2021; (10(16)) doi:10.3390/jcm10163474.

Pathogenic Mechanisms Underlying Idiopathic Pulmonary Fibrosis.

Moss BJ, Ryter SW, Rosas IO

Annual review of pathology 2022; (17()):515-546 doi:10.1146/annurev-pathol-042320-030240.

Three-Month FVC Change: A Trial Endpoint for Idiopathic Pulmonary Fibrosis Based on Individual Participant Data Meta-analysis.

Khan FA, Stewart I, Moss S, et al.

American journal of respiratory and critical care medicine 2022; (205(8)):936-948 doi:10.1164/rccm.202109-2091OC.

Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis.

Mei Q, Liu Z, Zuo H, et al.

Frontiers in pharmacology 2021; (12()):797292 doi:10.3389/fphar.2021.797292.

The efficacy of gabapentin for the treatment of refractory cough associated with interstitial lung disease: study protocol for a randomized, double-blind and placebo-controlled clinical trial.

Gao R, Xu X, Wang S, et al.

Trials 2022; (23(1)):165 doi:10.1186/s13063-022-06059-5.

Clinical evidence for improving exercise tolerance and quality of life with pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: A systematic review and meta-analysis.

Lei S, Li X, Xie Y, Li J

Clinical rehabilitation 2022; (36(8)):999-1015 doi:10.1177/02692155221095481.

Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases.

Chiner-Vives E, Cordovilla-Pérez R, de la Rosa-Carrillo D, et al.

Archivos de bronconeumologia 2022; (58 Suppl 1()):39-50 doi:10.1016/j.arbres.2022.03.011.

Applications of cryobiopsy in airway, pleural, and parenchymal disease.

DeMaio A, Thiboutot J, Yarmus L

Expert review of respiratory medicine 2022; (16(8)):875-886 doi:10.1080/17476348.2022.2122444.

Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography.

Khanna D, Distler O, Cottin V, et al.

Journal of scleroderma and related disorders 2022; (7(3)):168-178 doi:10.1177/23971983211064463.

Russian Registry of Idiopathic Pulmonary Fibrosis: Clinical Features, Treatment Management, and Outcomes.

Chikina S, Cherniak A, Merzhoeva Z, et al.

Life (Basel, Switzerland) 2023; (13(2)) doi:10.3390/life13020435.

Challenges in the diagnosis of idiopathic pulmonary fibrosis: the importance of a multidisciplinary approach.

Comes A, Sgalla G, Ielo S, et al.

Expert review of respiratory medicine 2023; (17(4)):1-11 doi:10.1080/17476348.2023.2199156.

The causal relationship between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis: a bidirectional two-sample Mendelian randomisation study.

Reynolds CJ, Del Greco M F, Allen RJ, et al.

The European respiratory journal 2023; (61(5)) doi:10.1183/13993003.01585-2022.

Mood disorder in idiopathic pulmonary fibrosis: response to pulmonary rehabilitation.

Edwards GD, Polgar O, Patel S, et al.

ERJ open research 2023; (9(3)) doi:10.1183/23120541.00585-2022.

A survival analysis of idiopathic pulmonary fibrosis in the context of antifibrotic therapy in Saudi Arabia.

Khan MA, Ghamdi BA, Alhamadi M, et al.

Annals of thoracic medicine 2023; (18(2)):79-85 doi:10.4103/atm.atm_264_22.

The Evolving Concept of the Multidisciplinary Approach in the Diagnosis and Management of Interstitial Lung Diseases.

Sanduzzi Zamparelli S, Sanduzzi Zamparelli A, Bocchino M

Diagnostics (Basel, Switzerland) 2023; (13(14)) doi:10.3390/diagnostics13142437.

Insight into the relationship between forced vital capacity and transfer of the lungs for carbon monoxide in patients with idiopathic pulmonary fibrosis.

Soumagne T, Quétant S, Guillien A, et al.

Respiratory medicine and research 2023; (84()):101042 doi:10.1016/j.resmer.2023.101042.

The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting.

Santos G, Fabiano A, Mota PC, et al.

Pulmonary pharmacology & therapeutics 2023; (83()):102261 doi:10.1016/j.pupt.2023.102261.

Diagnostic Approaches for Idiopathic Pulmonary Fibrosis.

Lee JH, Song JW

Tuberculosis and respiratory diseases 2024; (87(1)):40-51 doi:10.4046/trd.2023.0087.

Mediators of the association between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis.

Tao H, Dong Y, Chen X, Peng L

The European respiratory journal 2023; (62(6)) doi:10.1183/13993003.00323-2023.

Mechanisms and management of cough in interstitial lung disease.

Rasheed AZ, Metersky ML, Ghazal F

Expert review of respiratory medicine 2023; (17(12)):1177-1190 doi:10.1080/17476348.2023.2299751.

Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision.

Mackintosh JA, Keir G, Troy LK, et al.

Respirology (Carlton, Vic.) 2024; (29(2)):105-135 doi:10.1111/resp.14656.

Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial.

Wu Z, Spencer LG, Banya W, et al.

The Lancet. Respiratory medicine 2024; (12(4)):273-280 doi:10.1016/S2213-2600(23)00432-0.

Elucidating shared biomarkers in gastroesophageal reflux disease and idiopathic pulmonary fibrosis: insights into novel therapeutic targets and the role of angelicae sinensis radix.

Wu X, Xiao X, Fang H, et al.

Frontiers in pharmacology 2024; (15()):1348708 doi:10.3389/fphar.2024.1348708.

Epidemiology and Prognostic Significance of Cough in Fibrotic Interstitial Lung Disease.

Khor YH, Johannson KA, Marcoux V, et al.

American journal of respiratory and critical care medicine 2024; (210(8)):1035-1044 doi:10.1164/rccm.202311-2101OC.

Interstitial Lung Disease: A Review.

Maher TM

JAMA 2024; (331(19)):1655-1665 doi:10.1001/jama.2024.3669.

Update on Interstitial Pneumonias.

Carroll MB, Kanne JP, Martin Rother MD

Clinics in chest medicine 2024; (45(2)):419-431 doi:10.1016/j.ccm.2023.08.015.

Antifibrotic therapy in progressive pulmonary fibrosis: a review of recent advances.

Naqvi M, Hannah J, Lawrence A, et al.

Expert review of respiratory medicine 2024; (18(6)):397-407 doi:10.1080/17476348.2024.2375420.

Clinical implications of six-minute walk test in patients with idiopathic pulmonary fibrosis: a retrospective cohort study.

Kim MJ, Nathan SD, Kim HH, Kim HC

Therapeutic advances in respiratory disease 2024; (18()):17534666241275329 doi:10.1177/17534666241275329.

Interstitial lung disease in rheumatic diseases: an update of the 2018 review.

Atzeni F, Alciati A, Gozza F, et al.

Expert review of clinical immunology 2025; (21(2)):209-226 doi:10.1080/1744666X.2024.2407536.

SULF1 expression is increased and promotes fibrosis through the TGF-β1/SMAD pathway in idiopathic pulmonary fibrosis.

Tu M, Lu C, Jia H, et al.

Journal of translational medicine 2024; (22(1)):885 doi:10.1186/s12967-024-05698-3.

Interleukin-11 causes alveolar type 2 cell dysfunction and prevents alveolar regeneration.

Ng B, Huang KY, Pua CJ, et al.

Nature communications 2024; (15(1)):8530 doi:10.1038/s41467-024-52810-8.

Mortality-related risk factors of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.

Sun X, Lei S, Zhao H, et al.

Journal of thoracic disease 2024; (16(12)):8338-8349 doi:10.21037/jtd-23-1908.

Quality of life in idiopathic pulmonary fibrosis in Latin American countries.

Aguilar-Duran H, Fernández M, González-García M, et al.

BMC pulmonary medicine 2025; (25(1)):36 doi:10.1186/s12890-025-03506-2.

The role of vascularity and the fibrovascular interface in interstitial lung diseases.

Dietrich J, Kang A, Tielemans B, et al.

European respiratory review : an official journal of the European Respiratory Society 2025; (34(175)) doi:10.1183/16000617.0080-2024.

Comparison of the Effects of Nintedanib and Pirfenidone on Pulmonary Function Test Parameters and Radiological Findings in Patients with Idiopathic Pulmonary Fibrosis: A Real-Life Study.

Aycicek O, Keskin S, Haciosmanoglu M, et al.

Medicina (Kaunas, Lithuania) 2025; (61(2)) doi:10.3390/medicina61020283.

Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis.

Oldham JM, Neely ML, Wojdyla DM, et al.

Chest 2025; (168(2)):415-422 doi:10.1016/j.chest.2025.02.018.

Predictors of Long-Term Survival in Patients with Idiopathic Pulmonary Fibrosis: Data from the IPF-PRO Registry.

Kim HJ, Weber JM, Neely ML, et al.

Lung 2025; (203(1)):40 doi:10.1007/s00408-025-00797-4.

[Indications for Lung Transplantation - Updates Since the Last ISHLT Recommendations].

Kovacs Z, Benazzo A, Jaksch P

Zentralblatt fur Chirurgie 2025; (150(3)):256-260 doi:10.1055/a-2563-3691.

Current State of Fibrotic Interstitial Lung Disease Imaging.

Chelala L, Brixey AG, Hobbs SB, et al.

Radiology 2025; (316(1)):e242531 doi:10.1148/radiol.242531.

Gender-age-physiology stage and body mass index are useful predictors of nintedanib discontinuation and prognosis in patients with idiopathic pulmonary fibrosis and progressive fibrotic interstitial lung diseases.

Yazaki K, Matsuyama M, Satoh H, et al.

BMC pulmonary medicine 2025; (25(1)):564 doi:10.1186/s12890-025-04048-3.

Epidemiology of idiopathic pulmonary fibrosis: a population registry-based study.

Francesca G, Michele S, Anna P, et al.

Orphanet journal of rare diseases 2026; (21(1)):57 doi:10.1186/s13023-026-04210-y.